3 min read
Looking Back on Omicron: Checking our predictions against recent reports
When the Omicron variant of SARS-CoV-2 was first identified, we applied our molecular modeling methods to assess how...
Antibody Solutions helps biopharmaceutical companies advance their discovery of better diagnostics and therapeutics by delivering fit-for-purpose antibodies. Throughout our 25-year history, our clients have come to rely on us for highly specific scientific expertise, rigorous project management and a unique fee-for-service, pay-as-you-go model that keeps their IP in their hands.
When the Omicron variant of SARS-CoV-2 was first identified, we applied our molecular modeling methods to assess how...
On November 24, 2021, South Africa reported the identification of a new SARS-CoV-2 variant, B.1.1.529, to the World...
The Delta variant has quickly become the predominant strain of SARS-CoV-2. Based on molecular modeling studies,...
We tend to think of antibodies as being defined by their...
As scientists to the core, we frequently conduct our own studies and collaborate with fellow researchers to help advance innovations that deliver safer, more efficacious therapeutics and diagnostics to society.
biopharma companies served and counting
of clients return with new assignments
years of helping our clients succeed
of the top 10 research pharmas worldwide trust us
Let’s get the conversation started for your next custom antibody discovery project.